Press Release: Novartis Cosentyx(R) PMR data in -2-

References

1. Stone J, et al [abstract]. IVW 2026

2. Sun R, et al. Dermatol Ther (Heidelb). 2024;14(3):729-743;

3. Espígol-Frigolé G, et al. Lancet. 2023;402(10411):1459--72.

4. Gabriel SE, et al. Arthritis Rheum. 1997;40(10):1873--8.

5. Floris A, et al. Clin Rheumatol. 2022;41(1):19-31

6. Kevzara US PI. Available at: Kevzara Label (fda):

https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761037s013lbl.pdf

Accessed: 20 Jan 2025

7. Kevzara: EPAR - Product Information. Available at: Kevzara.

INN-sarilumab:

https://www.ema.europa.eu/en/documents/product-information/kevzara-epar-product-information_en.pdf

. Accessed: 20 Jan 2025

8. Dejaco C, et al. Oral Presentation #OP0116. EULAR 2026

9. Novartis Europharm Limited. Cosentyx(R) (secukinumab): Summary of Product

Characteristics. Available at: Cosentyx, INN-secukinumab:

https://www.ema.europa.eu/en/documents/product-information/cosentyx-epar-product-information_en.pdf

[Last accessed: May 2026].

10. Girolomoni G, Mrowietz U and Paul C. Psoriasis: rationale for targeting

interleukin-17. Br J Dermatol 2012; 167: 717-724.

11. Novartis Cosentyx shows clinically meaningful symptom improvements in

patients with hidradenitis suppurativa. [Press release]. Available at:

https://www.novartis.com/news/media-releases/novartis-cosentyx-shows-clinically-meaningful-symptom-improvements-patients-hidradenitis-suppurativa-pivotal-phase-iii-trials

[Last accessed: May 2026].

12. Novartis Cosentyx receives FDA approval for treatment of children and

adolescents with moderate to severe plaque psoriasis [Press release].

Available at:

https://www.novartis.com/news/media-releases/novartis-cosentyx-receives-fda-approval-treatment-children-and-adolescents-moderate-severe-plaque-psoriasis

[Last accessed: May 2026].

13. Novartis Cosentyx receives FDA approval for the treatment of children and

adolescents with enthesitis-related arthritis and psoriatic arthritis.

[Press release]. Available at:

https://www.novartis.com/news/media-releases/novartis-cosentyx-receives-fda-approval-treatment-children-and-adolescents-enthesitis-related-arthritis-and-psoriatic-arthritis

[Last accessed: May 2026].

14. Novartis Cosentyx receives positive CHMP opinion for expanded use in

childhood arthritic conditions. [Press release]. Available at:

https://www.novartis.com/news/media-releases/novartis-cosentyx-secukinumab-receives-positive-chmp-opinion-expanded-use-childhood-arthritic-conditions

[Last accessed: May 2026].

15. Novartis Cosentyx(R) receives FDA approval for pediatric patients aged

12+ with moderate to severe hidradenitis suppurativa. [Press release].

Available

at:https://www.novartis.com/news/media-releases/novartis-cosentyx-receive

s-fda-approval-pediatric-patients-aged-12-moderate-severe-hidradenitis-su

ppurativa [Last accessed: May 2026].

16. Cosentyx. Prescribing information. Novartis Pharmaceuticals Corp.

17. ClinicalTrials.gov. NCT05767034.[Last accessed: May2026]

18. Mazzantini

https://pubmed.ncbi.nlm.nih.gov/?term=Mazzantini+M&cauthor_id=22247343 M,

et al. J Rheumatol. 2012 Mar;39(3):552-7.

19. Hutchings A, et al. Arthritis Rheum. 2007;57(5):803--9

20. Mackie S.L, et al. Rheumatol Adv Pract. 2025 Dec 2;10(1):rkaf140. doi:

10.1093/rap/rkaf140

# # #

Novartis Media Relations

E-mail: media.relations@novartis.com

Novartis Investor Relations

Central investor relations line: +41

61 324 7944

E-mail: investor.relations@novartis.com

(END) Dow Jones Newswires

June 03, 2026 11:30 ET (15:30 GMT)